AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Jul - Copy of Newspaper Publication of Unaudited Financial Results for the quarter and half year ended 30th June 2026 is enclosed.
Source: Bse
Sanofi Consumer Healthcare India Limited (SANOFICONR)
Small CapPharma stocks · Small cap · NSE
Sanofi Consumer Healthcare India Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result29 Jul, 01:22 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
52Neutralfull bear SMA stack · SMA20 -8.9% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SANOFICONRD candles · FIT view-24.6%Latest close ₹3465.10 on 2026-10-19
Bar
-2.4%
RSI
18
MACD hist
-10.80
52W pos
1%
2026-10-19O ₹3548.70H ₹3554.50L ₹3455.80C ₹3465.10Vol 3,167 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SANOFICONRNifty PharmaNifty 500
- SANOFICONR
- -23.5%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -17.9 pp
Chart stats
19 Oct 2026- From 52W high
- -34.1%
- 52W range position
- 1%
- ATR (14)
- 2.8%
- Volume vs 20D
- 0.49x
- Avg traded value
- ₹2.4 Cr
- 20D price channel
- ₹3,455.8 - ₹4,081
₹5,255
₹3,455.8 - ₹5,255
₹98.2
Latest completed session
20-session average
17.9% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED64
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average50
Revenue +6.8% · PAT +13.1% YoY
Technical
Neutral52
Price trend and sector-relative-strength timing.
Valuation
Legacy model+33.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence83
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 50/100Rev +7% YoY · PAT +13% YoY · margin expansion · operating leverage
Filed 28 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹236 Cr | +6.8% | +3.1% |
| EBITDA | ₹89 Cr | +27.1% | +0.0% |
| Operating margin | 38.0% | +600 bps | -100 bps |
| PAT | ₹69 Cr | +13.1% | +1.5% |
| PAT margin | 29.2% | +164 bps | -45 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 32.50
- P/B
- 24.85
- EV/EBITDA
- 23.67
- Market Cap
- 8643.00Cr
Profitability
- ROE
- 71.60%
- ROCE
- 89.90%
- ROA
- 37.68%
- Dividend Y
- 2.00%
Growth (CAGR)
- Revenue 5Y
- 14.38%
- EPS 5Y
- 12.68%
- Revenue 3Y
- 78.00%
- EPS 3Y
- 78.00%
Balance Sheet
- Debt/Equity
- 0.06
- Interest Coverage
- 176.50×
- Altman Z
- 9.82
- Book Value
- 151.00
Cash Flow
- FCF Yield
- 2.12%
- FCF Positive Y
- 2/5
- OCF
- 175.00 Cr
- EPS TTM
- 115.49
Shareholding
- Promoter Hold
- 71.27%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 4%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 236+3.1% vs prev
Net Profit
₹ CrLatest: 69.0+1.5% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 18. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~9.7% over last month) — short-term momentum negative.
- RSI(14) at 18 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
22
RS percentile
Stage 4 Downtrend
1M return
-14.1%
3M return
-23.5%
6M return
-24.3%
1Y return
-25.6%
RS 1D
-1
RS 20D
-10
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 21.7% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.6%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 72.27-1.35%
RS vs Nifty 50072
Valuation & peers
U-Score 64 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 64 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · UNDERVALUEDValuation7/30
Growth15/25
Quality20/20
Balance Sheet12/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
64
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
64/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 33.3%.
- Quality contributes 20/20 to the score.
Main drags
- Valuation is weaker at 7/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Growth is weaker at 15/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
32.5
PB
24.9
EV/EBITDA
23.7
ROE
71.6%
ROCE
89.9%
FCF Yield
2.1%
Debt/Equity
0.1
MoS
+33.3%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
64
Previous: 64
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+33.3%
Previous: +33.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
64
64
64
64
64
64
64
64
64
64
64
64
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹626.4
-453.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹5,197.05
+33.3% MoS
PEG
1.60
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SUVEN
Small
Suven Life Sciences Limited
Healthcare Services
match 165
29
—
-81.5%
—
OVERVALUED
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 164
46
113.0
22.2%
-146%
FAIR VALUE
RPGLIFE
Small
RPG Life Sciences Limited
Healthcare Services
match 163
57
41.0
19.3%
+13%
FAIR VALUE
MOREPENLAB
Small
Morepen Laboratories Limited
Healthcare Services
match 163
20
63.1
5.3%
-1007%
OVERVALUED
SENORES
Small
Senores Pharmaceuticals Limited
Healthcare Services
match 163
35
48.2
13.4%
-2%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Sanofi Consumer Healthcare India Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
83Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 95th percentile of the scored universe and 92nd percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
8 docs text-extracted · 2 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
95th percentile
overall median 67 · Pharma: 92nd pctile, median 70 · Small: 96th pctile, median 66
Evidence depth
Financial-only
8 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
82
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 71.3%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.9%.
- ▸Debt/equity is 0.06.
Trust risks
- ▸2 older quarters in the 8-quarter window had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Sanofi Consumer Healthcare India Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementJun 2026
Jun 2026 · Intimation Of Record Date For Payment Of Final Dividend For FY 2025 27 May - 3rd AGM on 26 June 2026; book closure 20-26 June; final dividend record date 19 June 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Jun - Copies of newspaper advertisements regarding convening of 3rd Annual General Meeting of the Company scheduled to be held on 26th June 2026, through VC/OAVM facility.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Jun - Newspaper Advertisement of 3rd Annual General Meeting is enclosed.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 4 Jun
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 29 Jun - Shareholders approved PwC as statutory auditor from 25 May 2026 through 8th AGM in 2031.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 25 May - PwC appointed statutory auditor to fill vacancy; proposed 5-year term from AGM 2026 to 2031.
Source: Bse
AnnouncementApr 2026
Apr 2026 · Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 30 Apr - Kalyaniwalla & Mistry LLP resigned as Sanofi Consumer Healthcare India’s statutory auditor effective 30 April 2026 over fee dispute.
Source: Bse
Concall transcriptMar 2026
Mar 2026 · Transcript
Source: Bse
Investor presentationMar 2026
Mar 2026 · PPT
Source: Bse
Concall transcriptMar 2026
Mar 2026 · Transcript
Source: Bse
Investor presentationMar 2026
Mar 2026 · PPT
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.